Article
Refine
Year of publication
Document Type
- Article (91) (remove)
Has Fulltext
- yes (91)
Is part of the Bibliography
- no (91)
Keywords
- - (52)
- stroke (12)
- multiple sclerosis (7)
- cognition (5)
- epilepsy (5)
- seizure (5)
- Delphi study (4)
- biomarker (4)
- clinical (4)
- motor rehabilitation (4)
- outcome measures (4)
- CRPS (3)
- biomarkers (3)
- cerebrospinal fluid (3)
- diffusion tensor imaging (3)
- epidemiology (3)
- ischemic stroke (3)
- memory (3)
- migraine (3)
- prediction (3)
- rehabilitation (3)
- Alzheimer’s disease (2)
- Chorea (2)
- EEG (2)
- Functional connectivity (2)
- Magnetic resonance imaging, 7 T (2)
- Prefrontal cortex (2)
- Premanifest period (2)
- SARS-CoV-2 (2)
- anticonvulsants (2)
- autoimmunity (2)
- basal ganglia (2)
- cerebellum (2)
- chemical senses (2)
- classification (2)
- clinical trials (2)
- cognitive training (2)
- cross-reactivity (2)
- delirium (2)
- embodiment (2)
- executive functions (2)
- fatigue (2)
- free light chain kappa (2)
- network (2)
- neurology (2)
- non-motor manifestation (2)
- outcome (2)
- peptide sharing (2)
- quality of life (2)
- randomised trials (2)
- reliability (2)
- resting state fMRI (2)
- resting-state functional connectivity (2)
- sensorimotor cortex (2)
- social interactions (2)
- subacute stroke (2)
- taste (2)
- transcranial electrical stimulation (2)
- transcranial magnetic stimulation (2)
- voxel-based morphometry (2)
- ACC (1)
- ADEM (1)
- Acute cerebral ischemia (1)
- Acute ischaemic stroke (1)
- Aerobic treadmill training (1)
- Altersepilepsie (1)
- Amyloid-β (1)
- Angiitis (1)
- Angiogenesis (1)
- Angiopathy (1)
- Anticoagulation (1)
- Antiepileptic drugs (1)
- Antiepileptika (1)
- Antikoagulation (1)
- Aphasia (1)
- Aphasie (1)
- Arterial dissection (1)
- Autoimmunity (1)
- Brain health (1)
- Brainstem (1)
- CGRP (1)
- COVID-19 (1)
- COVID19 (1)
- CYP3A4 (1)
- Carotid arteries (1)
- Central sensitization (1)
- Cerebral angiogram (1)
- Cerebral infarcts in young adults (1)
- Cerebral ischaemia (1)
- Clinical trial (1)
- Complex regional pain syndrome (1)
- DLX proteins (1)
- DTI (1)
- Depression (1)
- Dissection (1)
- ER-stress (1)
- Electroencephalography (1)
- Encephalitis (1)
- Epilepsy (1)
- Epilepsy in old age (1)
- Epitopes (1)
- F-florbetaben PET (1)
- GI hormones (1)
- Gasdermin D (1)
- HCMV (1)
- HMGB1 (1)
- HTLV-1 (1)
- IL-6 (1)
- IL10 (1)
- ISP (1)
- Innate immunity (1)
- Ischaemic stroke (1)
- Klinische Studie (1)
- Logopädie (1)
- Long-COVID (1)
- MCI (1)
- MDSC (myeloid-derived suppressor cell) (1)
- Migraine (1)
- Montreal Cognitive Assessment (MoCA) (1)
- Multiple sclerosis (1)
- Neonates (1)
- Neuroinflammation (1)
- Neuropathology (1)
- Neutrophil extracellular traps (1)
- PSD (1)
- Paced Auditory Serial Addition Test (1)
- Patent foramen ovale (1)
- Patient recruitment (1)
- Perinatal infection (1)
- Posterior circulation (1)
- P‑gp (1)
- P‑gp-Transport (1)
- Rasch (1)
- Reiber’s diagram (1)
- Rekrutierung (1)
- Risk factors (1)
- Risk factors for stroke (1)
- Roux-en-Y gastric bypass (1)
- SDMT (1)
- Sleep (1)
- Slow wave sleep (1)
- Speech therapy (1)
- Spermidine (1)
- Stereotactic surgery (1)
- TMS (1)
- TNF-alpha (1)
- Transcranial direct current stimulation (1)
- Transkranielle Hirnstimulation (1)
- Turkish migrants (1)
- Vertebral artery dissection (1)
- Young (1)
- Young stroke (1)
- acquired demyelination syndrome (1)
- acute disseminated encephalomyelitis (1)
- adjuvant (1)
- age (1)
- aging (1)
- agreement (1)
- amyloid (1)
- anticonvulsant (1)
- antiepileptic drug (AED) (1)
- antiseizure medication (1)
- aphasia (1)
- arithmetic (1)
- autoimmune encephalitis (1)
- blink reflex (1)
- blood-brain barrier (1)
- body mass index (1)
- brain (1)
- brain mapping (1)
- brain plasticity (1)
- brain stimulation (1)
- brainstem (1)
- central nervous system (1)
- central sensitization (1)
- cerebrospinal fluid (CSF) (1)
- cerebrospinal fluid; (1)
- chronic pain (1)
- chronic post-stroke aphasia (1)
- cognitive intervention (1)
- cognitive neuroscience (1)
- cognitively normal (1)
- comorbidity (1)
- compensation account (1)
- complex regional pain syndrome (1)
- computational modeling (1)
- concussion (1)
- cortical thickness (1)
- corticospinal excitability (1)
- cost of illness (1)
- crp (1)
- deep learning (1)
- diagnosis (1)
- diffusion weighted imaging (1)
- disability (1)
- disease progression (1)
- disease-modifying therapy (1)
- drug trials (1)
- duration (1)
- economic burden (1)
- eigenvector centrality mapping (1)
- electric fields (1)
- electromyography (1)
- entropy (1)
- epilepsy of unknown origin (1)
- epileptic encephalopathies (1)
- evidence (1)
- evoked potentials (1)
- experimental stroke (1)
- extracellular vesicle (EV) (1)
- fNIRS (1)
- fetal and adult neurogenesis (1)
- fibrinogen (1)
- finger counting (1)
- finger-based training (1)
- finger-tapping task (1)
- frontal alpha activity (1)
- frontal beta activity (1)
- fronto-temporal cortex (1)
- functional outcome (1)
- functional recovery (1)
- gestural-verbal association (1)
- go/no-go task (1)
- granulocyte subpopulation (1)
- graph analysis (1)
- gray matter volume (1)
- guideline (1)
- head motion (1)
- headache (1)
- health care (1)
- health care delivery (1)
- health care quality (1)
- health costs (1)
- healthy aging (1)
- healthy older adults (1)
- healthy participants (1)
- hippocampal subfields (1)
- hippocampal volume (1)
- hippocampus (1)
- humans (1)
- imaging (1)
- imaging artifact (1)
- immune alterations (1)
- immune response (1)
- immune suppression (1)
- immunoglobulin (1)
- immunoglobulin synthesis (1)
- incidence (1)
- inflammation (1)
- information (1)
- innate immunity (1)
- insula (1)
- intensive speech-language therapy (1)
- interhemispheric inhibition (1)
- intra-class correlation (1)
- kappa free light chains (1)
- kappa-free light chains (KFLC) (1)
- knowledge (1)
- laboratory workflow (1)
- language disorders (1)
- language processing (1)
- late onset seizures (1)
- level of care (1)
- levetiracetam (1)
- machine learning (1)
- measurement system analysis (1)
- memory performance (1)
- metrology (1)
- microvasculature (1)
- monocyte subpopulation (1)
- morbidity (1)
- mortality (1)
- motor cortex (1)
- motor evoked potentials (1)
- motor outcome (1)
- navigation (1)
- neural antibodies (1)
- neurodegenerative diseases (1)
- neuroimaging (1)
- neurological diseases (1)
- neuropathic pain (1)
- neurophysiology (1)
- neuroplasticity (1)
- neuropsychiatric diseases (1)
- neuropsychological (1)
- non-MS patients (1)
- non-invasive brain stimulation (1)
- nucleus accumbens (1)
- obesity (1)
- object-location memory (1)
- older adults (1)
- oligoclonal IgG (1)
- outpatient (1)
- peptide (1)
- perfusion (1)
- peripheral nervous system (1)
- person ability (1)
- pituitary surgery (1)
- polypharmacy (1)
- postoperative cognitive dysfunction (1)
- postoperative delirium (1)
- preclinical Alzheimer's disease (1)
- predictors (1)
- preventive medicine (1)
- primary motor cortex (1)
- prognosis (1)
- prognostic factors (1)
- prognostic model (1)
- protein analytic (1)
- public health (1)
- questionnaire (1)
- random noise stimulation (1)
- randomized controlled trial (1)
- recovery (1)
- regulatory monocytes (1)
- reproducibility of results (1)
- research (1)
- resveratrol (1)
- review (1)
- risk factors (1)
- sTREM2 (1)
- safety (1)
- schizophrenia (1)
- screening tool (1)
- seasonal (1)
- seizures (1)
- serious adverse events (1)
- serum (1)
- sifap1 (1)
- similarity (1)
- single-digit addition (1)
- sleep (1)
- spatial transformation (1)
- spermidine (1)
- spine surgery (1)
- stress (1)
- stroke rehabilitation (1)
- subacute (1)
- subbase-5 effect (1)
- subjective cognitive decline (1)
- sun (1)
- task dependency (1)
- task difficulty (1)
- telephone interview (1)
- template magnetic resonance images (1)
- thalamus (1)
- tractography (1)
- transcranial direct current stimulation (1)
- treatment (1)
- unfolded and integrated stress response (1)
- vaccine (1)
- vascular risk factors (1)
- vessel size imaging (1)
- viral infections (1)
- white matter hyperintensities (1)
- white matter integrity (1)
Institute
- Klinik und Poliklinik für Neurologie (91) (remove)
Publisher
- Frontiers Media S.A. (38)
- MDPI (18)
- S. Karger AG (9)
- SAGE Publications (6)
- Wiley (6)
- BMJ Publishing Group (4)
- Springer Nature (4)
- Nature Publishing Group (2)
- American Medical Association (1)
- Elsevier (1)
Abstract
Head motion during magnetic resonance imaging (MRI) induces image artifacts that affect virtually every brain measure. In parallel, cross‐sectional observations indicate a correlation of head motion with age, psychiatric disease status and obesity, raising the possibility of a systematic artifact‐induced bias in neuroimaging outcomes in these conditions, due to the differences in head motion. Yet, a causal link between obesity and head motion has not been tested in an experimental design. Here, we show that a change in body mass index (BMI) (i.e., weight loss after bariatric surgery) systematically decreases head motion during MRI. In this setting, reduced imaging artifacts due to lower head motion might result in biased estimates of neural differences induced by changes in BMI. Overall, our finding urges the need to rigorously control for head motion during MRI to enable valid results of neuroimaging outcomes in populations that differ in head motion due to obesity or other conditions.
Objective
To evaluate individual and group long-term efficacy and safety of erenumab in individuals with episodic migraine (EM) for whom 2–4 prior preventatives had failed.
Methods
Participants completing the 12-week double-blind treatment phase (DBTP) of the LIBERTY study could continue into an open-label extension phase (OLEP) receiving erenumab 140 mg monthly for up to 3 years. Main outcomes assessed at week 112 were: ≥50%, ≥75% and 100% reduction in monthly migraine days (MMD) as group responder rate and individual responder rates, MMD change from baseline, safety and tolerability.
Results
Overall 240/246 (97.6%) entered the OLEP (118 continuing erenumab, 122 switching from placebo). In total 181/240 (75.4%) reached 112 weeks, 24.6% discontinued, mainly due to lack of efficacy (44.0%), participant decision (37.0%) and adverse events (AEs; 12.0%). The ≥50% responder rate was 57.2% (99/173) at 112 weeks. Of ≥50% responders at the end of the DBTP, 36/52 (69.2%) remained responders at ≥50% and 22/52 (42.3%) at >80% of visits. Of the non-responders at the end of the DBTP, 60/185 (32.4%) converted to ≥50% responders in at least half the visits and 24/185 (13.0%) converted to ≥50% responders in >80% of visits. Change from baseline at 112 weeks in mean (SD) MMD was −4.2 (5.0) days. Common AEs (≥10%) were nasopharyngitis, influenza and back pain.
Conclusions
Efficacy was sustained over 112 weeks in individuals with difficult-to-treat EM for whom 2–4 prior migraine preventives had failed. Erenumab treatment was safe and well tolerated, in-line with previous studies.
Trial registration number NCT03096834
Abstract
Objective
This study was undertaken to calculate epilepsy‐related direct, indirect, and total costs in adult patients with active epilepsy (ongoing unprovoked seizures) in Germany and to analyze cost components and dynamics compared to previous studies from 2003, 2008, and 2013. This analysis was part of the Epi2020 study.
Methods
Direct and indirect costs related to epilepsy were calculated with a multicenter survey using an established and validated questionnaire with a bottom‐up design and human capital approach over a 3‐month period in late 2020. Epilepsy‐specific costs in the German health care sector from 2003, 2008, and 2013 were corrected for inflation to allow for a valid comparison.
Results
Data on the disease‐specific costs for 253 patients in 2020 were analyzed. The mean total costs were calculated at €5551 (±€5805, median = €2611, range = €274–€21 667) per 3 months, comprising mean direct costs of €1861 (±€1905, median = €1276, range = €327–€13 158) and mean indirect costs of €3690 (±€5298, median = €0, range = €0–€11 925). The main direct cost components were hospitalization (42.4%), antiseizure medication (42.2%), and outpatient care (6.2%). Productivity losses due to early retirement (53.6%), part‐time work or unemployment (30.8%), and seizure‐related off‐days (15.6%) were the main reasons for indirect costs. However, compared to 2013, there was no significant increase of direct costs (−10.0%), and indirect costs significantly increased (p < .028, +35.1%), resulting in a significant increase in total epilepsy‐related costs (p < .047, +20.2%). Compared to the 2013 study population, a significant increase of cost of illness could be observed (p = .047).
Significance
The present study shows that disease‐related costs in adult patients with active epilepsy increased from 2013 to 2020. As direct costs have remained constant, this increase is attributable to an increase in indirect costs. These findings highlight the impact of productivity loss caused by early retirement, unemployment, working time reduction, and seizure‐related days off.
Abstract
Background and purpose:Diagnosing a patient with headache as a migraineur is critical for state-of-the-art migrainemanagement. Screening tools are imperative means to improve the diagnostic yield in the primary care settings andspecialized clinics. This study aims to translate and assess the diagnostic accuracy of a German version of theID Migraine™as a widely used and efficient screening instrument.
Methods:
The Functional Assessment of Chronic Illness Therapy translation methodology was used to translate theoriginal three-itemID Migraine™, including a fourth question for aura, from the English language into the German language.Diagnostic accuracy of the GermanID Migraine™and predictors of false screening results were assessed among patientspresenting to a headache outpatient clinic of a tertiary care center in Germany over a 6-month period.
Results:
The translation procedure yielded a harmonized GermanID Migraine™and its diagnostic accuracy was assessedin 105 patients (80 female, 46.5+17.2 years of age), including 79 patients (75.2%) with migraine. The three-item GermanID Migraine™provides a sensitivity of 99%, specificity of 68%, and positive and negative predictive values of 90% and 95%,respectively, using a cutoff of2. Positive and negative predictive values in a general headache population are estimated tobe 74% and 98%, respectively. The aura question identified 18 out of 20 migraineurs with aura.
Conclusions:
The GermanID Migraine™is an accurate screening tool for migraine even in a challenging population of aspecialized outpatient clinic. Its diagnostic accuracy indicates a potential utility for screening in primary health care.
Einleitung/Hintergrund
DC_TRAIN_APHASIA ist eine multizentrische, randomisiert-kontrollierte Studie, die seit November 2019 unter Federführung der Universitätsmedizin Greifswald durchgeführt wird (ClinicalTrials.gov Identifier: NCT03930121). Die Studie untersucht, ob adjuvante transkranielle Gleichstromstimulation („transcranial direct current stimulation“, tDCS) den Erfolg einer 3‑wöchigen intensiven Sprachtherapie bei chronischer Aphasie steigern kann.
Material und Methode
Bis Ende 2024 sollen bundesweit 130 Patient:innen eingeschlossen werden. Die Entwicklung innovativer Rekrutierungsstrategien stellt seit Beginn der Studie eine Herausforderung dar. Neben gängigen Rekrutierungsmethoden wie der direkten Ansprache von Menschen mit Aphasie in Kliniken, Logopädiepraxen, Rehabilitationseinrichtungen und Selbsthilfegruppen wurden Radiowerbespots, Fernsehbeiträge und Auftritte in sozialen Medien erprobt.
Zwischenergebnisse
Bis zum aktuellen Zeitpunkt konnten 110 Patient:innen in die Studie eingeschlossen werden. Zum größten kurzzeitigen Rücklauf führte die Rekrutierung über einen Fernseh- bzw. Radiobeitrag. Den größten langfristigen Rücklauf ergab die Rekrutierung über Logopädie- und Neurologiepraxen, Selbsthilfegruppen und soziale Medien. Teilnehmer:innen berichteten als „Testimonials“ positiv von der Sprachtherapie und der Anwendung von tDCS, die sich als gut verträglich erwies.
Diskussion
Die multizentrische Studie DC_TRAIN_APHASIA prüft die Wirksamkeit von tDCS als adjuvante Applikation für intensive Sprachtherapie bei chronischer Aphasie. Die vorliegende Übersicht soll künftigen Studien als Leitfaden zur Rekrutierung von Stichproben dienen, die Menschen mit eingeschränkten kommunikativen Fähigkeiten umfassen.
Background: Intensive speech-language therapy (SLT) can promote recovery from chronic post-stroke aphasia, a major consequence of stroke. However, effect sizes of intensive SLT are moderate, potentially reflecting a physiological limit of training-induced progress. Transcranial direct current stimulation (tDCS) is an easy-to-use, well-tolerated and low-cost approach that may enhance effectiveness of intensive SLT. In a recent phase-II randomized controlled trial, 26 individuals with chronic post-stroke aphasia received intensive SLT combined with anodal-tDCS of the left primary motor cortex (M1), resulting in improved naming and proxy-rated communication ability, with medium-to-large effect sizes.
Aims: The proposed protocol seeks to establish the incremental benefit from anodal-tDCS of M1 in a phase-III randomized controlled trial with adequate power, ecologically valid outcomes, and evidence-based SLT.
Methods: The planned study is a prospective randomized placebo-controlled (using sham-tDCS), parallel-group, double-blind, multi-center, phase-III superiority trial. A sample of 130 individuals with aphasia at least 6 months post-stroke will be recruited in more than 18 in- and outpatient rehabilitation centers.
Outcomes: The primary outcome focuses on communication ability in chronic post-stroke aphasia, as revealed by changes on the Amsterdam-Nijmegen Everyday Language Test (A-scale; primary endpoint: 6-month follow-up; secondary endpoints: immediately after treatment, and 12-month follow-up). Secondary outcomes include measures assessing linguistic-executive skills, attention, memory, emotional well-being, quality of life, health economic costs, and adverse events (endpoints: 6-month follow-up, immediately after treatment, and 12-month follow-up).
Discussion: Positive results will increase the quality of life for persons with aphasia and their families while reducing societal costs. After trial completion, a workshop with relevant stakeholders will ensure transfer into best-practice guidelines and successful integration within clinical routine.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03930121.
Background: Stereotactic electroencephalography (SEEG) is an invasive diagnostic tool for localizing the epileptic zone in patients with medically refractory focal epilepsy. Despite technical and imaging advances in guiding the electrode placement, vascular injury is still one of its most serious complications. Object: To investigate the usefulness of intraoperative cerebral C-arm CT angiogram (CCTA) in avoiding intracranial hemorrhagic complications during SEEG electrode implantation. Methods: Trajectory data from 12 patients who underwent SEEG electrode implantation were studied in detail. This included an analysis of the implantation of 146 SEEG electrodes, which were guided by intraoperative CCTA, as well as the standard planning based on preoperative contrast-enhanced MRI. In addition, a prospective analysis of SEEG hemorrhagic complications using the studied methodology was performed in a total of 87 patients receiving 1,310 electrodes. Results: There was no complication related to the CCTA itself. Intraoperative CCTA entailed modification of the original trajectory based on the preoperative MRI in 27 of 146 electrode implantations (18.5%). In 10 of them, a severe vascular complication was adverted by intraoperative CCTA. The safety of this new approach was also confirmed by the analysis of postinterventional CT, which revealed a symptomatic hematoma caused by 1 single electrode out of the 1,310 implanted. Conclusions: This study showed that intraoperative CCTA in addition to preoperative MRI is useful in guiding a safer SEEG electrode implantation. The combination of both imaging modalities essentially minimizes the risk of serious hemorrhagic complications.
Background
Fatigue is a common symptom in patients with multiple sclerosis. Several studies suggest that outdoor temperature can impact fatigue severity, but a systematic study of seasonal variations is lacking.
Methods
Fatigue was assessed with the Fatigue Scale for Motor and Cognitive Functions (FSMC) in a temperate climatic zone with an average outdoor temperature of 8.8°C. This study included 258 patients with multiple sclerosis from 572 visits temporally distributed over the year. The data were adjusted for age, sex, cognition, depression, disease severity, and follow-up time. Linear regression models were performed to determine whether the temporal course of fatigue was time-independent, linearly time dependent, or non-linearly time dependent.
Results
Fatigue was lowest during January (mean FSMC: 49.84) and highest during August (mean FSMC: 53.88). The regression analysis showed the best fit with a model that included months + months2, which was a non-linear time dependency. Mean FSMC per month correlated significantly with the average monthly temperature (ρ = 0.972; p < 0.001).
Conclusion
In multiple sclerosis, fatigue showed a natural temporal fluctuation. Fatigue was higher during summer compared to winter, with a significant relationship of fatigue with outdoor temperature. This finding should be carefully taken into account when clinically monitoring patients over time to not interpret higher or lower scores independent of seasonal aspects.
The Role of Vascular Risk Factors in Post-Stroke Delirium: A Systematic Review and Meta-Analysis
(2022)
Vascular risk factors may predispose to post-stroke delirium (PSD). A systematic review and meta-analysis were performed by searching PubMed, Web of Science, and Scopus. The primary outcome was the prevalence of vascular risk factors in PSD vs. non-PSD patients. Odds ratios (ORs) with 95% confidence intervals (CIs) and mean differences (MDs) with 95% CIs were calculated for categorical and continuous variables, respectively. Fixed effects or random effects models were used in case of low- or high-statistical heterogeneity, respectively. We found an increased prevalence of atrial fibrillation (OR = 1.74, p = 0.0004), prior stroke (OR = 1.48, p < 0.00001), coronary artery disease (OR = 1.48, p < 0.00001), heart failure (OR = 2.01, p < 0.0001), and peripheral vascular disease (OR = 2.03, p < 0.00001) in patients with vs. without PSD. PSD patients were older (MD = 5.27 y, p < 0.00001) compared with their non-PSD counterparts. Advanced age, atrial fibrillation, prior stroke, coronary artery disease, heart failure, and peripheral vascular disease appeared to be significantly associated with PSD.
Metrological methods for word learning list tests can be developed with an information theoretical approach extending earlier simple syntax studies. A classic Brillouin entropy expression is applied to the analysis of the Rey’s Auditory Verbal Learning Test RAVLT (immediate recall), where more ordered tasks—with less entropy—are easier to perform. The findings from three case studies are described, including 225 assessments of the NeuroMET2 cohort of persons spanning a cognitive spectrum from healthy older adults to patients with dementia. In the first study, ordinality in the raw scores is compensated for, and item and person attributes are separated with the Rasch model. In the second, the RAVLT IR task difficulty, including serial position effects (SPE), particularly Primacy and Recency, is adequately explained (Pearson’s correlation R=0.80) with construct specification equations (CSE). The third study suggests multidimensionality is introduced by SPE, as revealed through goodness-of-fit statistics of the Rasch analyses. Loading factors common to two kinds of principal component analyses (PCA) for CSE formulation and goodness-of-fit logistic regressions are identified. More consistent ways of defining and analysing memory task difficulties, including SPE, can maintain the unique metrological properties of the Rasch model and improve the estimates and understanding of a person’s memory abilities on the path towards better-targeted and more fit-for-purpose diagnostics.
Free light chains (FLC) are a promising biomarker to detect intrathecal inflammation in patients with inflammatory central nervous system (CNS) diseases, including multiple sclerosis (MS). The diagnostic use of this biomarker, in particular the kappa isoform of FLC (“KFLC”), has been investigated for more than 40 years. Based on an extensive literature review, we found that an agreement on the correct method for evaluating KFLC concentrations has not yet been reached. KFLC indices with varying cut-off values and blood-CSF-barrier (QAlbumin) related non-linear formulas for KFLC interpretation have been investigated in several studies. All approaches revealed high diagnostic sensitivity and specificity compared with the oligoclonal bands, which are considered the gold standard for the detection of intrathecally synthesized immunoglobulins. Measurement of KFLC is fully automated, rater-independent, and has been shown to be stable against most pre-analytic influencing factors. In conclusion, the determination of KFLC represents a promising diagnostic approach to show intrathecal inflammation in neuroinflammatory diseases. Multicenter studies are needed to show the diagnostic sensitivity and specificity of KFLC in MS by using the latest McDonald criteria and appropriate, as well as standardized, cut-off values for KFLC concentrations, preferably considering non-linear formulas such as Reiber’s diagram.
Objective: Extracellular vesicles (EV) are sub-1 μm bilayer lipid coated particles and have been shown play a role in long-term cardiovascular outcome after ischemic stroke. However, the dynamic change of EV after stroke and their implications for functional outcome have not yet been elucidated.
Methods: Serial blood samples from 110 subacute ischemic stroke patients enrolled in the prospective BAPTISe study were analyzed. All patients participated in the PHYS-STROKE trial and received 4-week aerobic training or relaxation sessions. Levels of endothelial-derived (EnV: Annexin V+, CD45–, CD41–, CD31+/CD144+/CD146+), leukocyte-derived (LV: Annexin V+, CD45+, CD41–), monocytic-derived (MoV: Annexin V+, CD41–, CD14+), neuronal-derived (NV: Annexin V+, CD41–, CD45–, CD31–, CD144–, CD146–, CD56+/CD171+/CD271+), and platelet-derived (PV: Annexin V+, CD41+) EV were assessed via fluorescence-activated cell sorting before and after the trial intervention. The levels of EV at baseline were dichotomized at the 75th percentile, with the EV levels at baseline above the 75th percentile classified as “high” otherwise as “low.” The dynamic of EV was classified based on the difference between baseline and post intervention, defining increases above the 75th percentile as “high increase” otherwise as “low increase.” Associations of baseline levels and change in EV concentrations with Barthel Index (BI) and cardiovascular events in the first 6 months post-stroke were analyzed using mixed model regression analyses and cox regression.
Results: Both before and after intervention PV formed the largest population of vesicles followed by NV and EnV. In mixed-model regression analyses, low NV [−8.57 (95% CI −15.53 to −1.57)] and low PV [−6.97 (95% CI −13.92 to −0.01)] at baseline were associated with lower BI in the first 6 months post-stroke. Patients with low increase in NV [8.69 (95% CI 2.08–15.34)] and LV [6.82 (95% CI 0.25–13.4)] were associated with reduced BI in the first 6 months post-stroke. Neither baseline vesicles nor their dynamic were associated with recurrent cardiovascular events.
Conclusion: This is the first report analyzing the concentration and the dynamic of EV regarding associations with functional outcome in patients with subacute stroke. Lower levels of PV and NV at baseline were associated with a worse functional outcome in the first 6 months post-stroke. Furthermore, an increase in NV and LV over time was associated with worse BI in the first 6 months post-stroke. Further investigation of the relationship between EV and their dynamic with functional outcome post-stroke are warranted.
Clinical Trial Registration: clinicaltrials.gov/, identifier: NCT01954797.
The cortical silent period (CSP), assessed with transcranial magnetic stimulation (TMS), provides insights into motor cortex excitability. Alterations in the CSP have been observed in multiple sclerosis (MS), although a comparison of the sometimes contradictory results is difficult due to methodological differences. The aim of this study is to provide a more profound neurophysiological understanding of fatigue’s pathophysiology and its relationship to the CSP. Twenty-three patients with MS, along with a matched control group, underwent comprehensive CSP measurements at four intensities (125, 150, 175, and 200% resting motor threshold), while their fatigue levels were assessed using the Fatigue Scale for Motor and Cognitive Functions (FSMC) and its motor and cognitive subscore. MS patients exhibited a significantly increased CSP duration compared to controls (p = 0.02), but CSP duration was not associated with the total FSMC, or the motor or cognitive subscore. Our data suggest a systematic difference in MS patients compared to healthy controls in the CSP but no association with fatigue when measured with the FSMC. Based on these results, and considering the heterogeneous literature in the field, our study highlights the need for a more standardized approach to neurophysiological data collection and validation. This standardization is crucial for exploring the link between TMS and clinical impairments in diseases like MS.
Background: Stroke patients are at risk of acquiring secondary infections due to stroke-induced immune suppression (SIIS). Immunosuppressive cells comprise myeloid-derived suppressor cells (MDSCs) and immunosuppressive interleukin 10 (IL-10)-producing monocytes. MDSCs represent a small but heterogeneous population of monocytic, polymorphonuclear (or granulocytic), and early progenitor cells (“early” MDSC), which can expand extensively in pathophysiological conditions. MDSCs have been shown to exert strong immune-suppressive effects. The role of IL-10-producing immunosuppressive monocytes after stroke has not been investigated, but monocytes are impaired in oxidative burst and downregulate human leukocyte antigen—DR isotype (HLA-DR) on the cell surface.
Objectives: The objective of this work was to investigate the regulation and function of MDSCs as well as the immunosuppressive IL-10-producing monocytes in experimental and human stroke.
Methods: This longitudinal, monocentric, non-interventional prospective explorative study used multicolor flow cytometry to identify MDSC subpopulations and IL-10 expression in monocytes in the peripheral blood of 19 healthy controls and 27 patients on days 1, 3, and 5 post-stroke. Quantification of intracellular STAT3p and Arginase-1 by geometric mean fluorescence intensity was used to assess the functionality of MDSCs. In experimental stroke induced by electrocoagulation in middle-aged mice, monocytic (CD11b+Ly6G−Ly6Chigh) and polymorphonuclear (CD11b+Ly6G+Ly6Clow) MDSCs in the spleen were analyzed by flow cytometry.
Results: Compared to the controls, stroke patients showed a relative increase in monocytic MDSCs (percentage of CD11b+ cells) in whole blood without evidence for an altered function. The other MDSC subgroups did not differ from the control. Also, in experimental stroke, monocytic, and in addition, polymorphonuclear MDSCs were increased. The numbers of IL-10-positive monocytes did not differ between the patients and controls. However, we provide a new insight into monocytic function post-stroke since we can report that a differential regulation of HLA-DR and PD-L1 was found depending on the IL-10 production of monocytes. IL-10-positive monocytes are more activated post-stroke, as indicated by their increased HLA-DR expression.
Conclusions: MDSC and IL-10+ monocytes can induce immunosuppression within days after stroke.
Background: Many regions worldwide reported a decline of stroke admissions during the early phase of the coronavirus disease 2019 (COVID-19) pandemic. It remains unclear whether urban and rural regions experienced similar declines and whether deviations from historical admission numbers were more pronounced among specific age, stroke severity or treatment groups.
Methods: We used registry datasets from (a) nine acute stroke hospitals in Berlin, and (b) nine hospitals from a rural TeleNeurology network in Northeastern Germany for primary analysis of 3-week-rolling average of stroke/TIA admissions before and during the COVID-19 pandemic. We compared course of stroke admission numbers with regional cumulative severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) infections. In secondary analyses, we used emergency department logs of the Berlin Charité University hospital to investigate changes in age, stroke severity, and thrombolysis/thrombectomy frequencies during the early regional Sars-CoV-2 spread (March and April 2020) and compared them with preceding years.
Results: Compared to past years, stroke admissions decreased by 20% in urban and 20-25% in rural hospitals. Deviations from historical averages were observable starting in early March and peaked when numbers of regional Sars-CoV-2 infections were still low. At the same time, average admission stroke severity and proportions of moderate/severe strokes (NIHSS >5) were 20 and 20–40% higher, respectively. There were no relevant deviations observed in proportions of younger patients (<65 years), proportions of patients with thrombolysis, or number of thrombectomy procedures. Stroke admissions at Charité subsequently rebounded and reached near-normal levels after 4 weeks when the number of new Sars-CoV-2 infections started to decrease.
Conclusions: During the early pandemic, deviations of stroke-related admissions from historical averages were observed in both urban and rural regions of Northeastern Germany and appear to have been mainly driven by avoidance of admissions of mildly affected stroke patients.
One of the great challenges the world faces in terms of health care is the increasing number of
people living with neuro-disabilities that affect their ability to participate in societal activities.
Various neurological conditions such as stroke, multiple sclerosis, or Parkinson’s disease, to name
just a few, change cognitive, sensory, or motor capacities, alter the emotional well-being of those
affected, and lead to disability in their everyday lives.
Over the last few decades, aging populations and reduced mortality in many regions of the world
have increased the number of people living with neuro-disabilities considerably, an effect that is
still ongoing (1): for 2017, the worldwide prevalence of stroke (thousands) has been estimated to
be as high as 104178.7 (95% confidence interval, 95% CI 98454.0–110125.0), and years lived with
disabilities (YLD) (counts in thousands) caused by stroke were reported to amount to 18695.4
(95% CI 13,574–23686.9). The stroke-related increase in YLD (percentage change in counts)
was 40% (95% CI 38.4–41.4) from 1990 to 2007 and another 43.6% (39.6–47.8) during only 10
years from 2007 to 2017. The numbers are similarly impressive for other neurological disorders
(i.e., dementias, Parkinson’s disease, epilepsy, multiple sclerosis, motor neuron disease, headache
disorders, and others). Taken together, their worldwide prevalence (in thousands) in 2017 was
3121435.3 (95% CI 2951124.5–3316268.0), while YLD (thousands) in 2017 were 3121435.3 (95%
CI 2951124.5–3316268.0), with an increase in YLD by 35.1% (95% CI 31.9–38.1) from 1990 to 2007
and by a further 17.8% (95% CI 15.8–20.2) from 2007 to 2017.
These numbers not only demonstrate the huge global burden of disease and prevailing
neuro-disabilities, but they indicate a considerable increase in the number of people living with
neuro-disabilities with an accelerating dynamic over time (for stroke).
Background
There is a lack of data concerning socioeconomic outcome and quality of life (QoL) in patients after status epilepticus (SE) in Germany.
Patients and methods
Adult patients treated between 2011 and 2015 due to SE at the university hospitals in Frankfurt, Greifswald, and Marburg were asked to fill out a questionnaire regarding long-term outcome of at least 3 months after discharge. The SE cohort consisted of 25.9% patients with an acute symptomatic, 42% with a remote symptomatic and previous epilepsy, 22.2% with a new-onset remote symptomatic, and 9.9% with other or unknown etiology. A matched case–control analysis was applied for comparison with patients with drug refractory epilepsy and seizure remission, both not previously affected by SE.
Results
A total of 81 patients (mean age: 58.7 ± 18.0 years; 58% female) participated. A non-refractory course was present in 59.3%, while 27.2% had a refractory SE (RSE) and 13.6% had a superrefractory SE (SRSE). Before admission, a favorable modified Rankin Scale (mRS) of 0–3 was found in 82.7% (67/81), deteriorating to 38.3% (31/81) (p = 0.003) at discharge. The majority returned home [51.9% (42/81)], 32.1% entered a rehabilitation facility, while 12.3% were transferred to a nursing home and 3.7% to another hospital. The overall mRS at follow-up did not change; 61.8% (45/74) reached an mRS of 0–3. In RSE and SRSE, the proportion with a favorable mRS increased from 45.5% at discharge to 70% at follow-up, while QoL was comparable to a non-refractory SE course. Matched epilepsy controls in seizure remission were treated with a lower mean number of anticonvulsants (1.3 ± 0.7) compared to controls with drug refractory epilepsy (1.9 ± 0.8; p < 0.001) or SE (1.9 ± 1.1; p < 0.001). A major depression was found in 32.8% of patients with SE and in 36.8% of drug refractory epilepsy, but only in 20.3% of patients in seizure remission. QoL was reduced in all categories (QOLIE-31) in SE patients in comparison with patients in seizure remission, but was comparable to patients with drug refractory epilepsy.
Discussion
Patients after SE show substantial impairments in their QoL and daily life activities. However, in the long term, patients with RSE and SRSE had a relatively favorable outcome comparable to that of patients with a non-refractory SE course. This underlines the need for efficient therapeutic options in SE.
Subjective cognitive decline (SCD) is considered an early risk stage for dementia due to Alzheimer's disease (AD) and the development of pathological brain changes, such as the aggregation of amyloid-beta (amyloid-β) plaques. This study evaluates the association between specific features of SCD and cerebral amyloid-β load measured by positron emission tomography (PET) with 18F-florbetaben in 40 cognitively normal older individuals. Global amyloid-β, as well as regional amyloid-β load for the frontal, temporal, parietal, and cingulate cortex, was quantified. Specific features of SCD, such as subjective cognitive complaints and worry, were assessed using the 39-item Everyday Cognition Scales and the 16-item Penn State Worry Questionnaire. Spearman's rank partial correlation analyses, adjusted for age and apolipoprotein E ε4 status, were conducted to test the associations between specific features of SCD and cerebral amyloid-β load. The severity of subjective cognitive complaints in everyday memory and organization was positively correlated with amyloid-β load in the frontal cortex. In addition, the severity of subjective cognitive complaints in everyday planning was positively correlated with amyloid-β load in the parietal cortex. Higher levels of worry were associated with higher amyloid-β load in the frontal cortex. After correction of the PET data for partial volume effects, these associations were reduced to trend level. In conclusion, the severity of subjective cognitive complaints and the level of trait worry were positively associated with cortical amyloid-β burden, particularly in the frontal and parietal cortex. Further studies are required to elucidate the direction of these associations in order to develop strategies to prevent amyloid deposition and cognitive decline.